作者
Robert F Betts, Marcio Nucci, Deepak Talwar, Marcelo Gareca, Flavio Queiroz-Telles, Roger J Bedimo, Raoul Herbrecht, Guillermo Ruiz-Palacios, Jo-Anne H Young, John W Baddley, Kim M Strohmaier, Kimberly A Tucker, Arlene F Taylor, Nicholas A Kartsonis, Caspofungin High-Dose Study Group
发表日期
2009/6/15
期刊
Clinical infectious diseases
卷号
48
期号
12
页码范围
1676-1684
出版商
The University of Chicago Press
简介
Background . The standard caspofungin treatment regimen (50 mg/day after a 70-mg dose on day 1) is effective and well tolerated for the treatment of invasive candidiasis, but experience with higher doses of caspofungin is limited. We evaluated the safety and efficacy of caspofungin at 3 times the standard dosing regimen.
Methods . Patients with proven invasive candidiasis were randomized to receive a standard or high-dose (150 mg/day) caspofungin treatment regimen. Safety was assessed in all patients as treated. Efficacy was assessed as a secondary objective in a full-analysis-set population. A favorable overall response was defined as symptom resolution and microbiological clearance at the end of caspofungin therapy.
Results . A total of 204 patients were included in the safety analysis (104 received the standard regimen, and 100 …
引用总数
学术搜索中的文章
RF Betts, M Nucci, D Talwar, M Gareca… - Clinical infectious diseases, 2009